This meeting aims to demonstrate how to improve and introduce PSA testing across Europe in order to decrease PCa mortality. By presenting new evidence and analysis to support a better and targeted approach of PSA testing we will discuss how early diagnosis will improve outcomes in European PCa patients.

The audience will consist of high-level influencers from various fields. Policy makers, scientific experts, European associations, and representatives of European patient groups with an interest in cancer and prostate cancer, in particular, are invited to contribute to cancer control activities.

To get the most out of this event the number of available seats is limited and registration will be assigned on a first come, first serve basis.